Dataset related to article "Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity"

This record contains raw data related to article “Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity" <strong>Introduction: </strong>Biliary tract cancers (BTC) are rare malignancies arising from biliary system. Systemic therapy is the cornerstone for stage IV disease, with poor overall survival (OS). Evidence is lacking about safety and efficacy of local ablative treatments, such as surgery and stereotactic body radiotherapy (SBRT) in the context of metastatic BTC (mBTC). <strong>Materials and methods: </strong>We retrospectively analyzed clinical outcomes for a cohort of mBTC patients treated with SBRT for oligometastatic disease. Inclusion criteria were 1-5 distant metastases; SBRT with a dose/fraction of a least 5 Gy to a biological effective dose (BED) of at least 40 Gy considering an α/β of 10 Gy. Analyzed outcomes included local control (LC), distant progression-free survival (DPFS), PFS, and OS. <strong>Results: </strong>51 patients meeting the inclusion criteria. Primary tumor sites were intrahepatic cholangiocarcinoma (35%), extrahepatic cholangiocarcinoma (31%), ampullary adenocarcinoma (20%), gallbladder adenocarcinoma (14%). 21 patients were treated on liver lesions, 17 on nodal metastasis, 5 patients on lung lesions, 4 patients on recurrence along the extrahepatic bile duct. After a median follow-up of 14 months median OS was 13.7 months, 1- and 2-year OS were 58% and 41%, respectively. Node and lung as metastatic sites were associated with a longer OS (p &lt; 0.001). Median LC was 26.8 months, and intrahepatic cholangiocarcinoma was associated with longer LC (p = 0.036). Median DPFS was 11 months, with 1- and 2-year DPFS of 48% and 27.8%, respectively. Ten patients reported grade 1-2 toxicity and 2 cases of acute G3 biliary obstruction. <strong>Conclusions: </strong>Stereotactic body radiotherapy (SBRT) is feasible in the context of mBTC. OS and PFS results are promising, considering that our patients were heavily pre-treated with systemic therapy. Patients with nodal or lung relapse have better prognosis. Distant relapses remain the main pattern of failure, but treatment of all metastatic sites seems to improve DMFS.本数据集包含与论文《立体定向体部放疗治疗寡转移及复发性胆道癌：单中心疗效与毒性分析》相关的原始数据。**引言**：胆道癌（biliary tract cancer, BTC）是一类起源于胆道系统的罕见恶性肿瘤。全身治疗是IV期胆道癌的核心治疗手段，但患者总生存期（overall survival, OS）欠佳。目前针对手术、立体定向体部放疗（stereotactic body radiotherapy, SBRT）等局部消融治疗在转移性胆道癌（metastatic biliary tract cancer, mBTC）中的安全性与有效性的研究证据仍较为匮乏。**材料与方法**：本研究回顾性分析了一组因寡转移疾病接受SBRT治疗的mBTC患者的临床结局。纳入标准为存在1~5处远处转移；SBRT单次照射剂量不低于5 Gy，当α/β比值为10 Gy时，生物等效剂量（biological effective dose, BED）至少为40 Gy。本次分析的结局指标包括局部控制（local control, LC）、远处无进展生存期（distant progression-free survival, DPFS）、无进展生存期（progression-free survival, PFS）及OS。**结果**：本研究共纳入符合纳入标准的患者51例。原发肿瘤部位分布为：肝内胆管癌（35%）、肝外胆管癌（31%）、壶腹腺癌（20%）、胆囊腺癌（14%）。其中21例患者接受肝脏病灶的SBRT治疗，17例接受淋巴结转移灶治疗，5例接受肺部病灶治疗，4例接受肝外胆管复发灶治疗。中位随访时间为14个月，中位OS为13.7个月，1年及2年OS率分别为58%与41%。转移部位为淋巴结与肺部的患者OS显著更长（p < 0.001）。中位LC为26.8个月，肝内胆管癌患者的局部控制时间更长（p = 0.036）。中位DPFS为11个月，1年及2年DPFS率分别为48%与27.8%。共有10例患者出现1~2级毒性反应，2例发生急性3级胆道梗阻。**结论**：SBRT在mBTC的治疗中具备可行性。鉴于本研究纳入的患者均已接受过多线全身治疗，本次研究获得的OS与PFS结果颇具前景。伴淋巴结或肺部复发的患者预后更佳。远处复发仍是主要的治疗失败模式，但对所有转移灶进行治疗似乎可改善远端无转移生存期（distant metastasis-free survival, DMFS）。